Compare LOAN & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | CELU |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | United States | United States |
| Employees | N/A | 123 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 35.2M |
| IPO Year | 1999 | N/A |
| Metric | LOAN | CELU |
|---|---|---|
| Price | $4.33 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 18.3K | ★ 104.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.14% | N/A |
| EPS Growth | ★ 2.08 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $9,688,641.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | $76.00 |
| P/E Ratio | $12.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.24 | $1.01 |
| 52 Week High | $6.05 | $4.35 |
| Indicator | LOAN | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 48.66 |
| Support Level | $4.26 | $1.21 |
| Resistance Level | $4.59 | $1.33 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 38.88 | 49.99 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.